Allogene Therapeutics, Inc.
ALLO · NASDAQ
Market closed$1.79$0.00 (0.00%)After hours $1.80 · +0.56%
Key statistics
Previous close$1.79
Open$1.74
Day high$1.83
Day low$1.74
52-week high$4.46
52-week low$0.980000
Market cap436.53M
Volume4.92M
Average volume8.35M
P/E ratio-2.32
Forward P/E—
EPS-0.77
Dividend yield0.00%
Market context
Why it moved
ALLO stock showed virtually no net price movement today, trading in a narrow range with no significant company-specific news catalyst, as shares of Allogene Therapeutics remained essentially flat near recent lows amid continued investor caution around the clinical-stage biotech.
What is happening
Recent company-specific developments and publisher coverage.
The Clinical Trial Vanguard · July 16, 2026Allogene’s ALLO-316 Achieves 31% Response Rate in Advanced Renal Cell CarcinomaGlobeNewswire · July 15, 2026Allogene Therapeutics Announces Journal of ClinicalSeeking Alpha · July 4, 2026Allogene Therapeutics: High-Upside Bet On The Next Wave Of CAR-T Innovation (NASDAQ:ALLO)GlobeNewswire · May 13, 2026Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business UpdateLatham & Watkins LLP · April 16, 2026Latham & Watkins Advises on Allogene Therapeutics’ US$200.4 Million Public Offering of Common StockInvesting.com · April 10, 2026Jefferies initiates Allogene stock coverage with buy rating on cancer therapy potentialQuiver Quantitative · April 10, 2026Allogene Therapeutics to Host Conference Call on Interim Futility Analysis from ALPHA3 Trial of Cemacabtagene Ansegedleucel in LBCLStock Titan · March 2, 2026Cancer CAR T firm Allogene sets March 12 call on 2025 results Benzinga · July 15, 2026Allogene Therapeutics Publishes Data From Phase 1 TRAVERSE Trial Of ALLO-316 In Advanced Or Metastatic Renal Cell Carcinoma; Trial Shows 31% Confirmed Response Rate With Recommended Phase 2 Regimen; Robust Expansion And Tumor Infiltration Seen Mt Newswire · May 28, 2026Allogene Therapeutics CEO David Chang Steps Down Benzinga · May 13, 2026Allogene Therapeutics Q1 2026 Earnings Call Transcript Mt Newswire · May 13, 2026Allogene Therapeutics Q1 Net Loss Narrows Benzinga · May 13, 2026Allogene Therapeutics Enters Termination Agreement With Overland Therapeutics On May 12, 2026; Terminates Exclusive License Agreement With Overland Therapeutics Effective May 12, 2026; No Termination Payments Made In Connection With Termination Agreement; To Hold About 3% Of Overland Equity After Surrendering Portion For No Consideration Mt Newswire · May 13, 2026Earnings Flash (ALLO) Allogene Therapeutics Posts Q1 Loss $0.18, vs. FactSet Est of $0.19 Loss Benzinga · May 13, 2026Allogene Therapeutics Q1 EPS $(0.18) Beats $(0.19) Estimate Mt Newswire · April 21, 2026Allogene Therapeutics Cleared to Expand B-Cell Lymphoma Treatment Trial in South Korea, Australia